Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

NCT01975389 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01975389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
October 29, 2013
Completion date
April 3, 2017
Enrollment
10,564 (actual)
Sites
1,595

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease